AUG 19, 2026 · PHASE 2 TRIAL
A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy
ClinicalTrials.gov
This is a Phase 2 registry record with no reported results; the study is actively recruiting and designed to test a hypothesis about dose reduction and supplementation to prevent a known toxicity.
Reported
Planned enrollment1173
PhasePHASE 2
Primary outcome measureDifference of grade 2 or higher peripheral…